South Africa Gene Therapy Market to 2032

Overview

The South Africa Gene Therapy Market is expected to reach a 1,252.57 USD Billion by 2032 and is projected to grow at a CAGR of 24.79% from 2025 to 2032.

Revenue, 2024 (USD Billion)
360.94
Forecast, 2032 (USD Billion)
1,252.57
CAGR, 2024 - 2032
24.79%
Report Coverage
South Africa

South Africa Gene Therapy Market 2018-2032 USD Billion

South Africa Gene Therapy Market, Key Findings (2025-2032)

Market Growth and Projections:

  • Market Size (2024): 360.94 USD Billion
  • Projected Market Size (2032): 1,252.57 USD Billion
  • CAGR (2025-2032): 24.79%

Key Findings of South Africa Gene Therapy Market

  • The South Africa Gene Therapy Market was valued at 360.94 USD Billion in 2024.
  • The South Africa Gene Therapy Market is likely to grow at a CAGR of 24.79% during the forecast period of 2024 to 2032.
  • In 2024, the Largest segment Viral Vector in Vector Segment accounted for the largest share of the market with a revenue of 283.12 USD Billion
  • The fastest growing segment Oncological Disorders in Application Segment grew Fastest with a CAGR of 27.56% during the forecast period from 2024 to 2032.

South Africa Gene Therapy Market Scope

South Africa Gene Therapy Market Segmentation & Scope
End User
  • Others
  • Research Institutes
  • Hospitals
  • Cancer Institutes
Application
  • Other Diseases
  • Neurological Disorders
  • Rare Diseases
  • Cardiovascular Diseases
  • Infectious Disease
  • Oncological Disorders
Method
  • In-Vivo
  • Ex-Vivo
Vector
  • Non-Viral Vector
  • Viral Vector

South Africa Gene Therapy Market Data Coverage Insights

Study Period 2024-2032
Base Year 2021
Unit Revenue in USD Billion
Market Value in 2024 360.94 USD Billion
Market Value in 2032 1,252.57 USD Billion
CAGR (2025-2032) 24.79%
Historic Data 2016-2023
Market Segments Covered End User,Application,Method,Vector

Regional Insights:

  • Leading Market (2024-2032): South Africa, leading in terms of revenue 360.94 USD Billion in 2024
    • Key Country: South Africa, leading in terms of revenue with value of 360.94 USD Billion in 2024.

Segments and Scope

  • South Africa Gene Therapy Market to 2032, By End User
    • Cancer Institutes is the largest segment in South Africa Gene Therapy Market to 2032 with a revenue of 163.91 USD Billion in the year 2024.
    • Cancer Institutes is the Fastest growing segment in South Africa Gene Therapy Market to 2032 with a Growth rate of 26.44 % in forecast period 2025-2032.
  • South Africa Gene Therapy Market to 2032, By Application
    • Oncological Disorders is the largest segment in South Africa Gene Therapy Market to 2032 with a revenue of 173.98 USD Billion in the year 2024.
    • Oncological Disorders is the Fastest growing segment in South Africa Gene Therapy Market to 2032 with a Growth rate of 27.56 % in forecast period 2025-2032.
  • South Africa Gene Therapy Market to 2032, By Method
    • Ex-Vivo is the largest segment in South Africa Gene Therapy Market to 2032 with a revenue of 276.76 USD Billion in the year 2024.
    • Ex-Vivo is the Fastest growing segment in South Africa Gene Therapy Market to 2032 with a Growth rate of 25.91 % in forecast period 2025-2032.
  • South Africa Gene Therapy Market to 2032, By Vector
    • Viral Vector is the largest segment in South Africa Gene Therapy Market to 2032 with a revenue of 283.12 USD Billion in the year 2024.
    • Viral Vector is the Fastest growing segment in South Africa Gene Therapy Market to 2032 with a Growth rate of 25.93 % in forecast period 2025-2032.

South Africa Gene Therapy Market Company Share Analysis

 
Company Name Company Share Analysis
Oxford Biomedica
Novartis AG
Kite Pharma Inc.
Biogen
Bristol-Myers Squibb Company
South Africa Gene Therapy Market Company Share Analysis

South Africa Gene Therapy Market Geographical Sales Distribution, 2018-2032 USD Billion

South Africa Gene Therapy Market Geographical Sales Distribution, 2018-2032 USD Billion

South Africa Gene Therapy Market Company Profiling

South Africa Gene Therapy Market Company Profiling
Frequently Asked Questions
The South Africa Gene Therapy Market is segmented based on Segmentation End User,Application,Method,Vector.
South Africa Gene Therapy Market was valued at USD 360.94(Revenue in USD Billion) in 2021.
South Africa Gene Therapy Market is projected to grow at a CAGR of 24.79% during the forecast period of 2024 to 2032.
The Viral Vector segment is expected to dominate the South Africa Gene Therapy Market, holding a largest market share of 283.12 USD Billion in 2024

South Africa Gene Therapy Market Scope

South Africa Gene Therapy Market Segmentation & Scope
End User
  • Others
  • Research Institutes
  • Hospitals
  • Cancer Institutes
Application
  • Other Diseases
  • Neurological Disorders
  • Rare Diseases
  • Cardiovascular Diseases
  • Infectious Disease
  • Oncological Disorders
Method
  • In-Vivo
  • Ex-Vivo
Vector
  • Non-Viral Vector
  • Viral Vector
Frequently Asked Questions
The South Africa Gene Therapy Market is segmented based on Segmentation End User,Application,Method,Vector.
South Africa Gene Therapy Market was valued at USD 360.94(Revenue in USD Billion) in 2021.
South Africa Gene Therapy Market is projected to grow at a CAGR of 24.79% during the forecast period of 2024 to 2032.
The estimated market value of the South Africa Gene Therapy Market for final year is USD 1,252.57 (USD Billion).

South Africa Gene Therapy Market Company Profiling

South Africa Gene Therapy Market Company Profiling
Frequently Asked Questions
The South Africa Gene Therapy Market is segmented based on Segmentation End User,Application,Method,Vector.
South Africa Gene Therapy Market was valued at USD 360.94(Revenue in USD Billion) in 2021.
South Africa Gene Therapy Market is projected to grow at a CAGR of 24.79% during the forecast period of 2024 to 2032.
The estimated market value of the South Africa Gene Therapy Market for final year is USD 1,252.57 (USD Billion).

Related Markets

HAVE A QUESTION?

Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.